Trial Profile

An open label, Phase II dose escalation and expansion study to evaluate the safety and efficacy of propagermanium (PPG) added to stable angiotensin receptor blocker therapy (irbesartan) for the treatment of patients with proteinuria

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Irbesartan/propagermanium (Primary) ; Propagermanium (Primary) ; Irbesartan
Indications Proteinuria; Renal failure
Focus Adverse reactions
Acronyms DMX-200
Sponsors Dimerix Bioscience

01 Feb 2018 Planned number of patients changed from 60 to 30.
14 Sep 2015 According to a Sun Biomedical media release, analysis of interim data from the first 15 patients in this study will be used to support the application for an Orphan Drug indication in patients with chronic kidney disease.
14 Sep 2015 According to a Sun Biomedical media release, the first patient has been enrolled in this study.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com